Loss of GPRC5D enhances the proliferative capacity and competitive fitness of myeloma upon anti-GPRC5D immunotherapy

Zenodo (CERN European Organization for Nuclear Research) 2026 Dataset Open access

Read full text
Authors: K. Martin Kortüm
DOI: 10.5281/zenodo.18619360
Cited by: 0

Fields of Study & Subjects

Multiple Myeloma Research and Treatments Monoclonal and Polyclonal Antibodies Research Lymphoma Diagnosis and Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
12 February 2026
Language
EN
Document type
Dataset